secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000899923-24-000054
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q3 revenue +11% to $213M, adj EPS $0.06; UNH to drop GeneSight coverage Jan 2025
--------------------------------------------------------------------------------

- Q3 revenue $213M (+11% YoY); GAAP net loss $22.1M improved from $61.3M loss; adj EBITDA $14.1M vs $1.4M.
- GAAP EPS -$0.24 vs -$0.75; adj EPS $0.06 vs -$0.03.
- FY2024 guidance raised: revenue $837-843M, adj EPS $0.12-0.14.
- UnitedHealthcare to stop covering GeneSight for commercial plans Jan 1, 2025; $10M Q3 / $40M TTM revenue at risk from UNH commercial.
- GeneSight revenue +34% YoY to $47.7M; total test volumes +6% to 376K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000054/0000899923-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000054/mygn-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000899923-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer